Forest and Almirall face three-month US delay with COPD drug
This article was originally published in Scrip
Executive Summary
The US FDA has extended the review period for Forest Laboratories and Almirall's aclidinium bromide, a long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD), by three months.